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Introduction
The osteoclast is a polykaryon whose capacity to mobilize bone 
requires the organization of its unique cytoskeleton. Thus, upon 
mineralized matrix recognition, the osteoclast polarizes its 
 fi brillar actin, eventuating in the formation of an acidifi ed extra-
cellular microenvironment wherein the resorptive machinery of 
the cell is activated. Failure to undergo this polarization event 
results in osteoclast dysfunction and, consequently, in varying 
degrees of osteopetrosis (Teitelbaum and Ross, 2003).
Soriano et al. (1991) made the surprising observation that 
the principal phenotype of c-Src–deleted mice resides in the 
skeleton. These animals develop severe osteopetrosis despite an 
abundance of osteoclasts. Thus, the disorder does not refl ect the 
failure of osteoclast recruitment but defective osteoclast func-
tion: specifi cally, disorganization of the cell’s actin cytoskeleton 
(Boyce et al., 1992). In fact, c-Src is the dominant Src family 
kinase (SFK) expressed in the osteoclast and regulates the cell’s 
cytoskeleton as an adaptor protein as well as through its kinase 
activity (Schwartzberg et al., 1997; Miyazaki et al., 2004).
Syk is another tyrosine kinase that modulates osteoclast 
function, at least in vitro (Faccio et al., 2003c; Mocsai et al., 
2004). The discovery of Syk in this regard was a consequence 
of the observation that immunoregulatory adaptor molecules 
such as Dap12 and FcRγ (Koga et al., 2004; Mocsai et al., 
2004), which bear immunoreceptor tyrosine-based activation 
motifs (ITAMs), are central to osteoclastogenesis, as mice lack-
ing both proteins are osteopetrotic because of the failure to gen-
erate osteoclasts (Koga et al., 2004). Alternatively, whether 
ITAM proteins impact the resorptive capacity of mature osteo-
clasts is unknown. The signaling events emanating from these 
proteins are activated by SFKs, which phosphorylate tyrosine 
residues within the ITAM (Pitcher and van Oers, 2003). These 
ITAM phosphotyrosines bind to and activate Syk (Futterer 
et al., 1998; Brdicka et al., 2005). However, the maintenance of 
ITAM-initiated Syk activity is under the aegis of the associated 
SFK (Brdicka et al., 2005). Activated ITAM-bound Syk targets 
guanine nucleotide exchange factors such as Vavs, leading to 
induction of the Rho GTPase Rac (Faccio et al., 2005).
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 In this study, we establish that the tyrosine kinase Syk is essential for osteoclast function in vitro and in vivo. Syk−/− osteoclasts fail to organize their cytoskeleton, 
and, as such, their bone-resorptive capacity is arrested. 
This defect results in increased skeletal mass in Syk−/− 
embryos and dampened basal and stimulated bone 
 resorption in chimeric mice whose osteoclasts lack the 
 kinase. The skeletal impact of Syk defi ciency refl ects 
 diminished activity of the mature osteoclast and not 
 impaired differentiation. Syk regulates bone resorption by 
its inclusion with the αvβ3 integrin and c-Src in a signal-
ing complex, which is generated only when αvβ3 is acti-
vated. Upon integrin occupancy, c-Src phosphorylates Syk. 
αvβ3-induced phosphorylation of Syk and the latter’s ca-
pa city to associate with c-Src is mediated by the immuno-
receptor tyrosine-based activation motif (ITAM) proteins 
Dap12 and FcRγ. Thus, in conjunction with ITAM-bearing 
proteins, Syk, c-Src, and αvβ3 represent an essential sig-
naling complex in the bone-resorbing osteoclast, and, 
therefore, each is a candidate therapeutic target.
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Integrins are αβ-transmembrane heterodimers and the 
principal cell/matrix recognition molecules. The osteoclast is 
particularly rich in the αvβ3 integrin, which mediates the 
 capacity of the cell to polarize, spread, and optimally degrade 
bone. Although less pronounced than that of c-Src–defi cient 
mice, those lacking αvβ3 develop enhanced bone mass as a 
 result of osteoclast dysfunction, again refl ecting a failure to 
 undergo cytoskeletal organization (McHugh et al., 2000; Faccio 
et al., 2003a).
The β3-integrin subunit is also expressed by platelets, 
wherein it associates with the αIIb chain. Similar to ITAM-
bearing proteins, αIIbβ3 recognizes Syk (Woodside et al., 
2001), which is also essential for integrin-mediated signaling 
in neutrophils (Mocsai et al., 2002). Interestingly, Syk binds 
directly to the β3 subunit of αIIbβ3 via the kinase SH2 do-
main but, unlike its interaction with ITAMs, does so indepen-
dently of the phosphorylation of integrin tyrosine residues 
(Woodside et al., 2001). In contrast to its association with 
phosphorylated ITAMs, recognition of the β3 subunit itself 
has no immediate impact on Syk activation, which occurs 
upon integrin/ligand  occupancy and is presumably secondary 
to the induction of an associated SFK (Woodside et al., 2001). 
As a result of αvβ3- induced Syk phosphorylation in the osteo-
clast, Vav3, which regulates the cell’s cytoskeleton, is acti-
vated (Faccio et al., 2005). Thus, Syk is downstream of 
immunoregulatory proteins such as Dap12 and FcRγ, which 
govern osteoclastogenesis, and of integrins, which regulate 
the cytoskeleton.
Because αvβ3 and its associated proteins are therapeutic 
targets in the context of pathological bone resorption (Murphy 
et al., 2005), we explored the mechanism by which the integrin 
regulates Syk in the osteoclast. We fi nd that Syk, c-Src, and 
αvβ3 form a ternary complex in the cell. Syk–c-Src binding 
 requires the terminal three amino acids of the β3 subunit and 
the kinase and C-terminal SH2 domains of Syk. The conse-
quence of αvβ3-ligand occupancy is the activation of c-Src, 
which, in an ITAM-dependent manner, phosphorylates Syk, 
thus organizing the osteoclast cytoskeleton. In keeping with 
these observations, Syk−/− osteoclasts have a disorganized 
 cytoskeleton leading to subnormal bone resorption in vitro 
and in vivo.
Results
Generation of Syk−/− radiation chimeras
To overcome the perinatal lethality of Syk−/− mice, we gener-
ated bone marrow chimeras by transplanting Syk−/− fetal liver 
cells into lethally irradiated wild-type (WT) recipients (Mocsai 
et al., 2002). Syk+/? (nongenotyped Syk+/+ or Syk+/− mice, 
which are phenotypically identical) fetal liver cells, which were 
injected into similar hosts, served as a control. These animals 
are designated Syk−/− and Syk+/? chimeras.
Figure 1. Syk defi ciency impairs osteoclast function 
but not differentiation in vitro. (A) BMMs derived from 
Syk+/? or Syk−/− chimeras were cultured with RANKL 
and MCSF for 5 d. Cells were stained for TRAP activity 
(red reaction product). (B) BMMs derived from Syk+/? 
or Syk−/− chimeras were cultured with RANKL and 
MCSF on dentin for 6 d. Actin ring formation was de-
termined by immunofl uorescence after FITC-phalloidin 
staining. (C) After 6 d, Syk+/? or Syk−/− osteoclasts 
were removed, and the dentin was stained with 
Coomassie brilliant blue to visualize resorption lacu-
nae. (D) Mature Syk−/− osteoclasts transduced with ei-
ther WT Syk, kinase-inactive SykK402R, or pMX vector 
were generated on dentin for 5 d with RANKL and 
MCSF. Cells were stained for TRAP activity and/or 
with FITC-phalloidin. The expression of Syk was deter-
mined by immunoblot assay of TCL Syk−/−. (E) BMMs 
were retrovirally transduced with WT Syk or empty 
 vector. Syk+/? and Syk−/− cells serve as positive and 
negative controls, respectively. The cells were placed on 
bone slices and differentiated into osteoclasts by expo-
sure to RANKL and MCSF. After 5 d, the osteoclasts 
were removed. Resorption pits were visualized by incu-
bation of the specimen with 20 μg/ml peroxidase-
 conjugated wheat germ agglutinin. (F) Medium was 
collected and assayed for CTx concentration. Actin 
serves as a loading control. Error bars represent SD. 
*, P < 0.01; **, P < 0.001. (G) Syk+/? or Syk−/− BMMs 
were cultured with MCSF and RANKL for 3 d. The cells 
were then lifted and either maintained in suspension 
(S) or plated on vitronectin (A) for 30 min. GTP-bound 
Rac1 and total Rac1 expression were determined, and 
the immunoblot was densitometrically quantitated.
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Donor and recipient cells are distinguished on the basis 
of surface antigen Ly-5.1 expression. Specifi cally, recipient 
mice (B6.SJL) express Ly-5.1, whereas donors (129.sv) do not. 
Purifi ed osteoclast precursors in the form of bone marrow mac-
rophages (BMMs) that recovered from Syk chimeras consist 
almost exclusively of donor cells (no Ly-5.1; Fig. S1 A, available 
at http:///www.jcb.org/cgi/content/full/jcb.200611083/DC1). 
Furthermore, Syk−/− chimeric BMMs express normal levels 
of receptor activator of nuclear factor κB (RANK) and the 
 macrophage colony–stimulating factor (MCSF) receptor c-Fms 
(Fig. S1 B).
Syk is required for osteoclast function 
but not differentiation
Syk is essential for T cell development, and we asked whether 
the same is true regarding the osteoclast. To this end, we cul-
tured Syk+/? and Syk−/− BMMs with MCSF and RANK 
ligand (RANKL) for 5 d. Syk-defi cient osteoclasts, which 
were ge nerated in culture, are distinctly abnormal. Both geno-
types  differentiate into tartrate-resistant acidic phosphatase 
(TRAP)–expressing multinucleated cells. However, Syk+/? 
BMMs form sheets of characteristic well-spread osteoclasts, 
whereas those lacking Syk are small with an irregular cre-
nated appearance, suggesting a cytoskeletal defect (Fig. 1 A). 
To ensure that these morphological abnormalities of Syk−/− 
osteoclasts do not refl ect arrested differentiation, we mea-
sured a series of markers of osteoclastogenesis in BMMs ex-
posed to MCSF and RANKL with time. The expression of 
characteristic osteo clastogenic proteins is not delayed in the 
Syk−/− cells (Fig. S2 A, available at http://www.jcb.org/cgi/
content/full/jcb.200611083/DC1) nor are intracellular signal-
ing events required for effi cient osteoclast differentiation 
(Fig. S2 B). These pathways include RANKL activation 
of nuclear factor κB, which is assessed by IκB-α phos-
phorylation and degradation, as well as JNK, ERK1/2, and 
p-38 phosphorylation. Furthermore, MCSF-driven ERK1/2 
and AKT phosphorylation is normal in Syk−/− osteoclasts 
(Fig. S2 C).
These data establish that Syk defi ciency does not impair 
osteoclast differentiation, and, therefore, we turned to osteoclast 
function. To this end, we plated BMMs on dentin, added MCSF 
and RANKL for 6 d, and stained the actin cytoskeleton with 
FITC-phalloidin. Documenting that the abnormal shape of the 
Syk−/− polykaryons refl ects deranged cytoskeletal organization, 
they are incapable of forming actin rings (Fig. 1 B). In keeping 
with their dysfunctional cytoskeleton, Syk−/−  osteoclasts are 
also unable to degrade mineralized matrix in vitro, as indicated 
by a complete absence of dentin-resorptive lacunae (Fig. 1 C). 
As expected, the failure of Syk-defi cient osteoclasts to spread 
and form actin rings is completely normalized by retroviral re-
constitution of the WT tyrosine kinase (Fig. 1 D) as is the cells’ 
resorptive capacities (Fig. 1, E and F). In contrast, the kinase-
inactive mutant SykK402R fails to res cue the mutant cell’s spread-
ing defect (Fig. 1 D). Thus, the  kinase activity of Syk is central 
to its capacity to organize the osteoclast cytoskeleton.
Rac is a downstream effector of αvβ3-mediated cytoskel-
etal organization (Faccio et al., 2005). To determine whether 
Rac signals downstream of αvβ3-activated Syk in committed 
osteoclast precursors, we cultured Syk+/? or Syk−/− BMMs in 
osteoclastogenic conditions for 3 d. The cells were lifted 
and maintained in suspension or replated on αvβ3 ligand for 
30 min. Densitometric analysis of Fig. 1 G reveals that αvβ3 
occu pancy increases Rac activation 1.8-fold in Syk+/? cells, 
whereas no detectable change (1.1-fold) occurs in the absence 
of the  tyrosine kinase.
Syk defi ciency impairs osteoclast 
function in vivo
Having established that Syk defi ciency impacts osteoclastic 
bone resorption in vitro, we asked whether the same obtains in 
vivo. Similar to the in vitro situation, osteoclast number in 
Syk−/− chimeric mice 2 mo after the generation of the animals 
is indistinguishable from that of irradiated controls transplanted 
with WT liver cells whether in the basal state or after stimula-
tion with the resorptive agonist parathyroid  hormone (PTH) 
(1–34) (Fig. 2 A). On the other hand, Syk-defi cient osteoclasts 
Figure 2. Syk defi ciency results in abnormal 
osteoclast function in vivo. (A) PTH(1–34) or 
vehicle was administered to Syk+/? or Syk−/− 
chimeras for 4 d. Calvariae were fi xed and 
stained for TRAP activity, and osteoclast (OC) 
number was histomorphometrically determined, 
*, P < 0.05; **, P < 0.01; PTH versus buffer. 
(B) TRAP-stained histological sections of calvaria 
of PTH-treated Syk+/? or Syk−/− chimeric mice. 
Osteoclasts (red reaction product) of PTH-treated 
Syk+/? mice reside in resorption lacunae and 
contain ruffl ed membranes (arrow), whereas 
most Syk−/− osteoclasts are smaller and are 
not juxtaposed to the bone. (C) Percentage of 
bone surface juxtaposed to osteoclasts in control 
and PTH-treated Syk+/? or Syk−/− mice. *, P < 
0.05 versus Syk−/−; +, P < 0.05 versus buffer. 
(D) Serum was collected from vehicle and PTH-
treated Syk+/? and Syk−/− chimeras. CTx was 
measured by ELISA. *, P < 0.01. Error bars 
represent SD.
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are small and appear incapable of adhering to the bone surface or 
forming well-demarcated resorption lacunae after receiving the 
bone-resorptive hormone (Fig. 2 B). Not only does Syk defi -
ciency reduce the percentage of bone surface covered by osteo-
clasts adherent to bone, but, unlike WT, the proportion of 
bone-apposed cells does not  increase in response to PTH (Fig. 
2 C). Confi rming an osteoclast defect in these Syk−/− chimeras, 
PTH(1–34)-enhanced serum levels of the global bone-resorptive 
marker CTx are blunted (Fig. 2 D).
For reasons unknown, Syk−/− chimeras survive only 
1–2 mo after transplantation, preventing the meaningful assess-
ment of skeletal mass with age. On the other hand, 18.5-d 
Syk−/− embryos have increased bone density as compared 
with Syk+/? littermates (Fig. 3 A and Fig. S3, available 
at http://www.jcb.org/cgi/content/full/jcb.200611083/DC1). 
Moreover, osteoclasts resident in Syk-deleted embryos have 
the same crenated appearance as their counterparts in ra dia-
tion chimeras (Fig. 3 B). In keeping with increased bone 
density, the marrow space of Syk−/− mice contains a network 
of trabeculae that is absent in their Syk/? counterparts. 
 Alternatively, growth plate morphology of the mutant mice 
is unremarkable.
Syk defi ciency does not impact 
osteoblast function
Osteoblasts may increase skeletal mass by accelerating bone 
formation or arresting osteoclast formation and function as a 
result of reduced RANKL or increased osteoprotegrin (OPG) 
expression. To address this issue in the context of Syk defi ciency, 
we cultured Syk+/? and Syk−/− calvarial osteoblasts in osteo-
genic conditions for 20 d, after which they were stained with 
Alizarin red. As seen in Fig. 4 (A and B), there is no apparent 
difference in the capacity of the two genotypically distinct 
 osteoblasts to generate mineralized bone nodules.
Next, we treated the same combination of osteoblasts with 
1,25-dihydroxyvitamin D3 or TNF-α, as each is a modulator 
of RANKL synthesis. Similar to their bone-forming capacity, 
Syk+/? and Syk−/− osteoblasts express equivalent amounts of 
RANKL and OPG mRNA in response to both agents (Fig. 4 C). 
Finally, and in keeping with the unaltered biological activity of 
Syk−/− osteoblasts, Syk protein is also not detectable by immuno-
blotting in their Syk+/? counterparts (Fig. 4 D).
Syk, c-Src, and the 𝛂v𝛃3 integrin form 
a trimolecular complex in osteoclasts
Osteoclasts defi cient in Syk, the αvβ3 integrin (McHugh et al., 
2000), or c-Src (Soriano et al., 1991) each have striking 
Figure 3. Bone density is increased in Syk−/− embryos. (A) Skeletons of 
18.5-d Syk+/? and Syk−/− embryos were fi xed in 95% ethanol and stained 
with Alcian blue and Alizarin red. Syk−/− forelimb and hindlimb bones are 
denser as indicated by increased Alizarin staining (arrows). (B) TRAP-
stained (red reaction product) histological sections of day 18.5 Syk+/? and 
Syk−/− embryo femurs. Arrows indicate the trabecular network in Syk−/− 
but not Syk+/? marrow space.
Figure 4. Syk does not regulate osteoblast function. 
(A and B) Syk+/? or Syk−/− primary calvaria osteo-
blasts were cultured with differentiation media (α-MEM 
containing 50 μg/ml ascorbic acid and 2 mM 
β-glycerophosphate) for 20 d. Bone nodule formation 
was visualized by Alizarin red staining. (C) Syk+/? or 
Syk−/− primary calvarial osteoblasts were cultured in 
α-MEM media (con), 10 nM 1,25-dihydroxyvitamin 
D3 (VitD), or 10 ng/ml TNF-α for 24 h. RANKL and 
OPG expression were analyzed by RT-PCR. Actin 
serves as loading control. (D) Syk+/? or Syk−/− pri-
mary calvarial osteoblasts were lysed, and Syk 
 expression was determined by immunoblotting. WT 
macrophage (Mϕ) lysate serves as a positive control.
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cyto skeletal defects eventuating in subnormal bone resorption. 
Furthermore, c-Src (Arias-Salgado et al., 2003) or Syk (Woodside 
et al., 2001) in other circumstances associates with the β3-
integrin cytoplasmic domain, prompting us to ask whether the 
three molecules form a complex in osteoclasts. To address this 
issue, we turned to β3−/− BMMs transduced with human β3 
(hβ3). These transductants express physiological levels of 
αvβ3 (Feng et al., 2001). Human constructs of the integrin 
were used because the WT cytoplasmic component is identical 
to its mouse counterpart, and an antibody that effectively re-
cognizes its extracellular domain is available. The cells were 
placed in MCSF and RANKL for 5 d to generate mature, ad-
herent osteoclasts. Total cell lysates (TCLs) were then immuno-
precipitated with anti–c-Src, anti-Syk antibodies, or irrelevant 
IgG. Both tyrosine kinases associate with αvβ3 in mature 
 osteoclasts (Fig. 5 A).
To determine whether formation of the kinase–integrin 
complexes depends on αvβ3 occupancy, we generated mono-
nuclear preosteoclasts by exposing BMMs to MCSF and 
RANKL for 3 d. In this circumstance, the cells are committed 
to the osteoclast phenotype as they express TRAP, αvβ3, and 
c-Src (Faccio et al., 2003b) but, unlike mature osteoclasts, are 
easily suspended. The cells were maintained in suspension or 
were adherent to the αvβ3 ligand vitronectin for 30 min. Reci-
procal immunoprecipitation and immunoblotting show that Syk 
associates with the integrin in an adhesion-dependent manner 
(Fig. 5 B). In contrast, β3–c-Src recognition is constitutive and 
is not impacted by integrin occupancy (Fig. 5 C).
The interaction of both Syk and c-Src with αvβ3 in osteo-
clasts suggests that the two kinases may coimmunoprecipitate. 
To address this issue, we cultured WT BMMs in MCSF with or 
without RANKL for 3 or 5 d. Syk immunoprecipitates and 
TCLs were then immunoblotted for c-Src content. Consistent 
with the progressive expression of c-Src as cells assume the 
 osteoclast phenotype, the kinase is increasingly abundant in 
Syk immunoprecipitates derived from MCSF- and RANKL-
containing cultures and is absent in those treated with MCSF 
alone (Fig. 5 D). Also, in contrast to c-Src, whose expression by 
macrophages is specifi c to the osteoclast phenotype, the pro-
duction of Syk is unaffected by time or RANKL.
To determine the functional role of the β3 integrin in 
c-Src–Syk association, WT or β3−/− BMMs were cultured with 
Figure 5. Syk, c-Src, and 𝛂v𝛃3 form a complex in osteoclasts. (A) β3−/− BMMs retrovirally transduced with hβ3WT were cultured with RANKL and MCSF 
for 5 d. Total cell lysate (TCL) was immunoprecipitated with anti-Syk or ant–c-Src antibodies or irrelevant IgG. Immunoprecipitates and TCLs were probed 
by Western blotting for β3-integrin, Syk, and c-Src content. (B and C) WT BMMs were cultured with MCSF and RANKL for 3 d. The cells were then lifted 
and either maintained in suspension (S) or plated on vitronectin (A) for 30 min. β3-integrin immunoprecipitates from each group of cells were probed by 
immunoblotting for β3-integrin and Syk content (B) or for c-Src content (C). (D) WT BMMs were cultured with MCSF alone or MCSF and RANKL for 3 or 
5 d. TCL was immunoprecipitated with anti-Syk antibody followed by c-Src and Syk immunoblotting. (E) TCL from WT or β3−/− osteoclasts was immuno-
precipitated with anti-Syk (top) or anti–c-Src (bottom) antibodies. Immunoprecipitates and TCLs were immunoblotted for c-Src and Syk content. (F) β3−/− BMMs 
were retrovirally transduced with hβ3 or pMX vector. The transductants were cultured in RANKL and MCSF for 5 d. Syk immunoprecipitates and TCLs were 
then immunoblotted for c-Src, Syk, or β3-integrin content. (G) WT preosteoclasts, which were generated by culturing BMMs in MCSF and RANKL for 3 d, 
were lifted and either plated on vitronectin (A) or maintained in suspension (S) for 30 min. c-Src and Syk content in Syk immunoprecipitates was determined 
by immunoblotting. (H) Suspended Syk+/? or Syk−/− preosteoclasts were plated on vitronectin. The percentage of spread cells was determined after 5 and 
10 min. *, P < 0.001 versus Syk+/?. Error bars represent SD.
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RANKL and MCSF for 5 d, after which we immunoprecipi-
tated c-Src or Syk and reciprocally immunoblotted the other. As 
shown in Fig. 5 E, association of the two tyrosine  kinases is 
substantially reduced in the absence of αvβ3, although the ex-
pression of neither c-Src nor Syk is altered. Confi rming its role 
in regulating c-Src–Syk recognition, retroviral reconstitution of 
β3-defi cient osteoclasts with the integrin subunit restores co-
immunoprecipitation of the kinases (Fig. 5 F).
We next asked whether the integrin’s state of occupancy 
impacts c-Src–Syk association. Committed preosteoclasts were 
once again generated by incubating WT BMMs in MCSF and 
RANKL for 3 d. The cells were lifted and either maintained in 
suspension or plated on vitronectin for 30 min. Syk immuno-
precipitates were then immunoblotted for c-Src and Syk content. 
Adhesion of preosteoclasts to αvβ3 ligand enhances c-Src–Syk 
coprecipitation in circumstances of equal Syk content (Fig. 5 G).
These data suggest that Syk mediates αvβ3 function in 
osteoclasts. Thus, we asked whether an essential property of the 
integrin, namely rapid spreading on αvβ3 ligand, is disturbed in 
the absence of Syk. To this end, committed preosteoclasts were 
suspended and replated on vitronectin-coated plates. In keeping 
with disturbed αvβ3 function, Syk defi ciency markedly reduces 
the capacity of preosteoclasts to rapidly spread on the integrin’s 
ligand(Fig. 5 H and Fig. S4, available at http://www.jcb.org/
cgi/content/full/jcb.200611083/DC1).
The terminal three amino acid residues 
of the 𝛃3-integrin cytoplasmic domain 
regulate c-Src–Syk association
c-Src directly associates with the distal three amino acids of the 
β3-subunit cytoplasmic domain in vitro and in transformed 
cells (Arias-Salgado et al., 2003, 2005). To determine whether 
this motif regulates c-Src–Syk interaction in the osteoclast, we 
substituted these residues with the C-terminal three amino acids 
of the β1-integrin chain to generate hβ3–hβ1(C3R) (Fig. 6 A; 
Arias-Salgado et al., 2005). hβ3–hβ1(C3R) or hβ3WT was retro-
virally transduced into β3−/− BMMs, which were then placed 
in osteoclastogenic conditions. TRAP staining of the cultures 
after 5 d demonstrates that the mutated construct yields small, 
poorly spread osteoclasts that are indistinguishable from those 
generated from naive β3−/− BMMs, whereas the WT subunit 
completely rescues the osteoclast phenotype (Fig. 6 B). This 
observation and the diminished coprecipitation of c-Src and 
Syk in the hβ3–hβ1(C3R)-bearing cells (Fig. 6 C) establish that 
the three terminal β3 amino acids are required for optimal asso-
ciation of the two kinases and their ability to organize the osteo-
clast cytoskeleton.
To further explore this issue, we asked whether the three 
terminal β3 residues regulate the integrin’s interaction with 
Syk and/or c-Src in the osteoclast. Thus, we transduced β3−/− 
BMMs with hβ3WT or hβ3–hβ1(C3R). After 5 d in MCSF and 
RANKL, the integrin constructs were immunoprecipitated, and 
the immunoprecipitates were blotted with anti-Syk or β3 anti-
bodies. Unlike transformed cells expressing αIIbβ3 (Woodside 
et al., 2001), Syk binds hβ3–hβ1(C3R) in the osteoclast and, 
for reasons unknown, does so more effectively than to hβ3WT 
(Fig. 6 D). However, this conundrum does not refl ect the 
enhanced affi nity of Syk for the β1 integrin in the absence of 
β3 (Fig.5, available at http://www.jcb.org/cgi/content/full/jcb
.200611083/DC1).
Syk phosphorylation in the context of αIIbβ3 does not 
depend on the presence of the two Y residues in the β3 cyto-
plasmic domain (Gao et al., 1997). On the other hand, 
αIIbβ3–Syk binding is arrested by the alanine mutation of 
β3Y747 (Woodside et al., 2001). We fi nd that unlike the plate-
let integrin, in which β3Y747F/Y752F promotes a bleeding dys-
crasia (Law et al., 1999), the same  double mutant does not 
impact the osteoclast (Feng et al., 2001). In keeping with 
this observation, Syk association with β3 is  unaltered by 
β3Y747F/Y752F (Fig. 6 E). In contrast to Syk, the binding of 
c-Src to hβ3 is arrested by the hβ3–hβ1(C3R) mutation 
(Fig. 6 F). Consistent with this observation, no c-Src–β3 
 association is evident upon deletion of the entire integrin 
Figure 6. The distal three amino acids of the 𝛃3-integrin cytoplasmic 
 domain mediate Syk–c-Src association. (A) Amino acid sequences of human 
(h) β3-integrin constructs used in this study. Letters in red refer to substituted 
β1-integrin subunit residues. (B–D) β3−/− BMMs transduced with hβ3WT 
or hβ3–hβ1(C3R) were cultured in the presence of RANKL and MCSF for 
5 d. (B) Cells were stained for TRAP activity. (C) Syk immunoprecipitates 
and TCLs were immunoblotted for c-Src and Syk content. (D) β3-integrin 
 immunoprecipitates and TCLs were immunoblotted for Syk and β3-integrin 
content. (E) β3−/− BMMs transduced with hβ3WT or hβ3Y747F/Y752F (hβ3 
2Y-2F) were cultured in the presence of RANKL and MCSF for 5 d. 
β3-integrin immunoprecipitates and TCLs were immunoblotted for Syk and 
β3-integrin content. (F) β3−/− BMMs transduced with hβ3WT, hβ3∆C, 
hβ3∆752–762, or hβ3–hβ1(C3R) were cultured in the presence of RANKL 
and MCSF for 5 d. β3-integrin immunoprecipitates and TCLs were immuno-
blotted for β3-integrin and c-Src content.
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 cyto plasmic domain (hβ3∆C) or its termination at residue 751 
(hβ3∆752–762).
c-Src mediates 𝛂v𝛃3-induced Syk activation 
in osteoclasts
Syk must be phosphorylated to induce its downstream targets 
and, when bound to the ITAM domain of immune response re-
ceptors, is activated via autophosphorylation (Pitcher and van 
Oers, 2003). To determine whether such is the case regarding its 
association with αvβ3 in the osteoclast, we suspended WT pre-
osteoclasts in the presence of the Syk kinase inhibitor piceatan-
nol (Pice; Calbiochem) or a carrier (DMSO). After 20 min, the 
cells were either maintained in suspension or replated on the 
αvβ3 ligand vitronectin. 30 min later, Syk immunoprecipitates 
were analyzed for phosphotyrosine content by immunoblotting. 
Fig. 7 A shows that Pice does not detectably impact adhesion-
induced Syk phosphorylation. Confi rming that it is an effective 
Syk kinase inhibitor in osteoclasts, Pice arrests integrin-
 mediated phosphorylation of the Syk downstream target Vav3 
(Fig. 7 B; Faccio et al., 2005).
We next transduced WT or kinase-inactive Syk 
(SykK402R) into Syk−/− BMMs. The cells were plated on vitro-
nectin, and tyrosine-phosphorylated Syk was measured. 
Consistent with our Pice-based studies, adherent Syk−/− 
preosteoclasts bearing kinase-inactive Syk undergo normal 
adhesion-associated tyrosine phosphorylation (Fig. 7 C). 
These data indicate that although Syk kinase activity is nec-
essary for organization of the osteoclast cytoskeleton (Fig. 
1 D), αvβ3-associated Syk is itself phosphorylated by another 
kinase. Given that αvβ3 induces Syk–c-Src interaction, the 
latter is a likely Syk kinase. In fact, SFK inhibitors diminish 
c-Src–Syk association (Fig. 7 D) and adhesion-induced Syk 
phosphorylation (Fig. 7 E). More specifi cally, Syk activation 
in response to αvβ3 occupancy is markedly reduced in Src−/− 
preosteoclasts (Fig. 7 F).
Having established that c-Src activates Syk in the osteo-
clast, we asked the reciprocal question: does αvβ3 occupancy 
activate c-Src, and, if so, is the event mediated by Syk? We have 
shown that the absence of Syk attenuates c-Src activity in the 
context of an entire population of preosteoclasts (Faccio et al., 
2003c). However, these previous experiments included both 
αvβ3 ligand–adherent and –nonadherent cells, the latter being 
abundant in the absence of Syk. As our present aim involved the 
impact of Syk on αvβ3-stimulated c-Src activity, we maintained 
Figure 7. c-Src mediates 𝛂v𝛃3-induced Syk activation in osteoclasts. (A and B) WT BMMs were cultured in RANKL and MCSF for 3 d. The preosteoclasts 
were lifted and preincubated in 10 μM piceatannol (Pice) or DMSO for 20 min. They were then plated on vitronectin (A) or maintained in suspension (S) 
for 30 min, after which tyrosine-phosphorylated Syk (A) or Vav3 (B) was determined by immunoblotting. (C) Syk−/− BMMs transduced with WT Syk, 
SykR195A, SykK402R, or pMX vector were cultured in RANKL and MCSF for 3 d. The preosteoclasts were lifted and plated on vitronectin for 30 min, after 
which phosphorylated tyrosine in Syk immunoprecipitates and TCLs was determined by immunoblotting. (D) WT BMMs were cultured in RANKL and MCSF 
for 3 d. The preosteoclasts were then suspended and preincubated in 2 μM SU6656 (+) or DMSO (−) for 20 min. After 30-min adhesion to vitronectin, 
Syk immunoprecipitates and TCLs were immunoblotted for c-Src and Syk. (E) WT BMMs cultured in RANKL and MCSF for 3 d were lifted and preincubated 
for 20 min in 10 μM PP2, 2 μM SU6656, or DMSO for 20 min. The cells were then plated on vitronectin (A) or maintained in suspension (S) for 30 min, 
after which phosphorylated tyrosine in Syk immunoprecipitates was determined by immunoblotting. (F) WT or c-Src−/− spleen cells were cultured in RANKL 
and MCSF for 3 d. The cells were lifted and either replated on vitronectin or maintained in suspension for 30 min, after which phosphorylated tyrosine in 
Syk immunoprecipitates was determined by immunoblotting. Syk, c-Src, and β-actin (loading control) content was also assessed in TCLs. (G) WT or Syk−/− 
BMMs were cultured in RANKL and MCSF for 3 d. The cells were lifted and either replated on vitronectin or maintained in suspension for 30 min. The 
plated cells were then rinsed with PBS to remove nonadherent cells. c-SrcY416 and β-actin (loading control) content was assessed by immunoblotting in TCLs 
of both suspended and adherent cells.
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Syk+/? or Syk−/− preosteoclasts on vitronectin for 30 min, after 
which nonadherent cells were removed. TCLs of the remaining 
adherent preosteoclasts, representing the population with occu-
pied αvβ3, were then immunoblotted for activated c-Src. Adhe-
sion to the αvβ3 ligand phosphorylates the activating residue 
c-SrcY416 equally in the presence or absence of Syk (Fig. 7 G). 
Thus, although αvβ3-associated c-Src activates Syk, the reci-
procal is not true.
ITAM-bearing proteins mediate 
𝛂v𝛃3-stimulated Syk activation
Syk and c-Src recognize and signal through ITAM-bearing 
 immunoreceptors as well as the αvβ3 integrin (Woodside, 2002). 
To determine whether interdependency exists between these 
two receptor-mediated signaling pathways in osteoclasts, we 
turned to osteopetrotic mice deleted of two essential osteoclasto-
genic ITAM immunoreceptors, namely Dap12 and FcRγ (Koga 
et al., 2004). In keeping with previous studies (Koga et al., 
2004; Mocsai et al., 2004), we fi nd that terminal osteoclasto-
genesis, which was induced in our system by 5-d exposure of 
spleen cells to RANKL and MCSF, is attenuated in Dap12−/−/
FcRγ−/− mice (unpublished data). Surprisingly, however, the 
appearance of TRAP-stained mutant cells after only 3 d in 
 osteoclastogenic medium is similar to WT (Fig. 8 A). Further-
more, the expression of β3-integrin mRNA (Fig. 8 B) and c-Src 
(Fig. 8 C) is also indistinguishable in the two genotypes at this 
earlier time. Next, Dap12−/−/FcRγ−/− day 3 preosteoclasts were 
lifted and maintained in suspension or replated on αvβ3 ligand 
for 30 min. Subsequent immunoprecipitation and phosphotyro-
sine immunoblotting shows that the adhesion-mediated activa-
tion of Syk is obviated in the absence of the two ITAM proteins 
(Fig. 8 D). Furthermore, integrin occupancy of Dap12−/−/
FcRγ−/− preosteoclasts fails to phosphorylate the Syk kinase 
target Vav3 but continues to activate c-Src, which is upstream of 
Syk in the αvβ3 signaling cascade (Fig. 8 E).
These data indicate that integrin activation of Syk requires 
ITAM immunoreceptors. If so, one would expect the disruption 
of Syk–ITAM association to blunt the tyrosine kinase’s capacity 
to organize the osteoclast cytoskeleton. To address this issue, we 
turned to SykR195A, which continues to bind the β3 integrin but 
not ITAM proteins (Gao et al., 1997; Woodside et al., 2001). We 
expressed WT Syk or this mutant of the C-terminal SH2 domain 
in Syk−/− preosteoclasts generated by 3-d exposure to RANKL 
and MCSF. The cells were suspended and replated on vitro-
nectin for 30 min. In this circumstance, the WT protein but not 
SykR195A is phosphorylated (Fig. 7 C), and Syk and c-Src no lon-
ger meaningfully associate (Fig. 8 F). These collective observa-
tions indicate that ITAM proteins mediate αvβ3-stimulated Syk 
activation. Importantly, WT Syk rescues the Syk−/− osteoclast 
cytoskeleton, but SykR195A fails to do so (Fig. 8 G). Therefore, 
αvβ3- and ITAM-bearing immunoreceptors function in tandem 
regarding the impact of c-Src–Syk on the osteoclast.
Discussion
Osteoclasts are characterized by a unique cytoskeleton that me-
diates the resorptive process. Upon contact with bone, the cell 
generates two polarized structures enabling it to degrade skele-
tal tissue. These include a villous organelle unique to the resorb-
ing osteoclast, which is known as the ruffl ed membrane, and the 
actin ring or sealing zone, which isolates the resorptive micro-
environment from the general extracellular space (Teitelbaum 
and Ross, 2003).
The β3-integrin knockout mouse serves as an important 
tool for determining the role of the osteoclast’s most abundant 
integrin in its capacity to resorb bone (McHugh et al., 2000). 
Failure to express αvβ3 results in dramatic alterations of the 
cell’s actin cytoskeleton, including failure to form actin rings or 
normal ruffl ed membranes in vivo. These abnormalities result in 
attenuated bone resorption.
The mechanisms by which c-Src exerts its effects in osteo-
clasts are complex. In the fi rst instance, it functions as an adaptor 
protein independent of its capacity to induce tyrosine phos-
phorylation (Schwartzberg et al., 1997). Alternatively, complete 
reversal of the functional abnormalities of c-Src–defi cient 
 osteoclasts also requires its kinase activity (Schwartzberg et al., 
1997; Miyazaki et al., 2004).
The similar cytoskeletal phenotypes of c-Src and αvβ3-
defi cient osteoclasts suggest a commonality of intracellular 
Figure 8. ITAM proteins mediate 𝛂v𝛃3-induced Syk activation in osteo-
clasts. (A–C) WT or Dap12−/−/FcRγ−/− (2KO) spleen cells were cultured 
in RANKL and MCSF for 3 d, after which the cells were stained for TRAP 
activity (A), analyzed for β3-integrin mRNA content by RT-PCR (B), and an-
alyzed for c-Src expression by immunoblotting (C). (D and E) WT or 
Dap12−/−/FcRγ−/− (2KO) spleen cells were cultured in RANKL and MCSF 
for 3 d. The cells were lifted and either replated on vitronectin (A) or main-
tained in suspension (S) for 30 min, after which Syk immunoblots were 
probed for phosphotyrosine content (D) or TCLs were immunoblotted for 
phosphorylated Vav3 and c-Srcp-Y416 (E). (F) Syk−/− BMMs transduced with 
WT Syk or SykR195A were cultured in RANKL and MCSF for 5 d. Syk immuno-
precipitates and TCLs were then immunoblotted for c-Src and Syk content. 
(G) Syk−/− BMMs were transduced with WT Syk, SykR195A, or empty vector 
(pMX). After 5-d exposure to RANKL and MCSF, the cells were stained for 
TRAP activity.
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 signaling. c-Src binds directly to the terminal three amino acids 
of the β3 subunit in the context of the platelet integrin αIIbβ3 
(Arias-Salgado et al., 2003), and we have established that the 
same residues regulate αvβ3–c-Src association in the osteo-
clast. However, the means by which c-Src is recruited to αvβ3 
in the osteoclast is not fully understood. A current model holds 
that Pyk2 and c-Cbl mobilize c-Src to the integrin (Sanjay et al., 
2001). In this paradigm, αvβ3 occupancy induces the phos-
phorylation of Pyk2Y402, which then activates c-Src by occupy-
ing its SH2 domain. Although provocative, these data await 
documentation that Cbl or Pyk2 deletion prompts a meaningful 
bone phenotype. Furthermore, although c-Src and c-Cbl phos-
phorylation depends on αvβ3 occupancy, this is not the case 
regarding Pyk2 (Faccio et al., 2003a). On the other hand, there 
is substantial evidence that Syk partners with c-Src, and, there-
fore, we asked whether these two nonreceptor tyrosine kinases 
impact the osteoclast in the context of the αvβ3 integrin.
Differentiation of Syk-defi cient BMMs into osteoclasts is 
not delayed as determined by the progressive expression of mark-
ers of the mature resorptive cell in the presence of RANKL and 
MCSF. Moreover, activation of many intracellular signals in-
duced by the two osteoclastogenic cytokines is not retarded in the 
mutant cells. Like those lacking c-Src or αvβ3, however, Syk−/− 
osteoclasts have a deranged cytoskeleton, as they fail to spread or 
form actin rings in vitro and are largely unattached to the bone 
surface in vivo. Failure of a kinase-inactive Syk mutant to rescue 
Syk−/− osteoclasts establishes that activated Syk is required to 
organize the cell’s cytoskeleton. Confi rming the functional sig-
nifi cance of these abnormalities, Syk−/− embryos have increased 
bone mass, and basal and PTH-stimulated bone  resorption are 
attenuated in radiation chimeric mice whose  osteoclasts lack 
the kinase. The morphological similarity of  osteoclasts lacking 
c-Src, αvβ3, or Syk raises the possibility that these molecules work 
in tandem in the osteoclast. In fact, we fi nd that each associates 
with the other two in the mature resorptive cell and that c-Src–
Syk interaction requires the presence of the liganded integrin.
The β3-integrin cytoplasmic domain consists of 47 amino 
acids, and we previously noted that of six candidate substitu-
tions, only one, the human mutation β3S752P, fails to rescue the 
dysfunctional β3-defi cient osteoclast (Feng et al., 2001). In the 
present study, we extend these data to include the terminal three 
residues of the subunit as essential for osteoclast cytoskeletal 
organization. The fact that the absence of this motif arrests both 
β3–c-Src and c-Src–Syk association provides compelling evi-
dence that the two tyrosine kinases partner with the integrin to 
regulate the osteoclast cytoskeleton. On the other hand, neither 
substitution of the three C-terminal β3 residues nor the absence 
of c-Src dampens Syk’s capacity to bind the integrin. Therefore, 
in osteoclasts, Syk binds to the β3 subunit independently of 
c-Src and at a site that is probably distinct from the SFK.
In contrast to the platelet (Law et al., 1999), mutation of 
the two β3 cytoplasmic domain tyrosine residues to phenyl-
alanine does not impact the osteoclast. This observation may be 
a result of the fact that although the β3 chain recognizes Syk via 
the latter’s N-terminal SH2 domain, it does so in a phospho-
tyrosine-independent manner (Gao et al., 1997). This is in keep-
ing with our fi nding that mutation of the two tyrosine residues 
in the β3 cytoplasmic domain does not alter its recognition of 
Syk in osteoclasts. This circumstance permits Syk in associa-
tion with αvβ3 to continue to activate downstream cytoskeletal-
organizing molecules such as Vav3 and Rac and explains the 
capacity of β3Y747F/Y752F to completely rescue β3−/− osteoclasts 
(Feng et al., 2001).
The earliest insights into the mechanisms by which Syk 
impacts the platelet and the osteoclast relate to its capacity to 
interact with ITAM-containing proteins (Woodside, 2002). In 
the osteoclast, these ITAM proteins include Dap12 and FcRγ 
(Koga et al., 2004; Mocsai et al., 2004). Although the deletion 
of each enhances bone mass, the elimination of both promotes 
severe osteopetrosis, an event mediated, at least in part, by Syk 
dysfunction. In contrast to the means by which its N-terminal 
SH2 domain associates with β3 integrin, Syk’s C-terminal SH2 
motif binds ITAM proteins via the classic mechanism of phos-
photyrosine recognition (Futterer et al., 1998). Given the indi-
vidual fl exibility of each Syk SH2 domain (Futterer et al., 1998), 
these observations suggest that Syk associates with αvβ3 and 
ITAM proteins in the same complex.
Deletion of both Dap12 and FcRγ arrests terminal osteo-
clastogenesis as a result of the failed expression of NFATc1 
(Koga et al., 2004). However, the absence of Syk does not impact 
the osteoclastogenic transcription factor. This observation is con-
sistent with the fact that osteoclasts lacking the kinase, like those 
deleted of the integrin, mature normally but fail to organize their 
cytoskeleton. Thus, although Syk is regulated by both αvβ3 and 
ITAM proteins, the impact of each on the osteoclast differs.
On the other hand, we fi nd that ITAM proteins are not 
 required for early commitment to the osteoclast phenotype, 
 enabling us to explore the role of Dap12 and FcRγ in αvβ3 
 activation of Syk and its downstream targets. Syk activation in 
osteoclasts is independent of its own kinase and occurs under 
the aegis of c-Src. Furthermore, Syk’s ability to undergo phos-
phorylation and associate with c-Src in the bone-resorptive cell 
depends on an intact ITAM-interactive C-terminal SH2 domain 
(Gao et al., 1997; Woodside et al., 2001). These data suggest a 
model in which Syk is fi rst recruited to the activated integrin at 
a site other than the three terminal amino acids (Fig. 9). Syk, in 
turn, functions as an adaptor for the integrin and ITAM proteins 
wherein the kinase interacts with the latter in an SH2 domain–
dependent manner. c-Src binds independently of integrin occu-
pancy to the distal β3 cytoplasmic domain, where it associates 
with and phosphorylates Syk upon αvβ3 occupancy. Impor-
tantly, these observations establish for the fi rst time that ITAM 
proteins not only regulate osteoclast function but the capacity 
of the mature resorptive cell to resorb bone as well. Thus, our 
data show that Syk is a nexus of a novel signaling pathway 
regulat ing osteoclast function and, like c-Src (Kamath et al., 
2003) and αvβ3 (Murphy et al., 2005), is a candidate anti–bone-
resorptive therapeutic target.
Materials and methods
Mice
Animals were housed in the animal care unit of the Washington University 
School of Medicine and were maintained according to guidelines of the 
Association for Assessment and Accreditation of Laboratory Animal Care. 
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All animal experimentation was approved by the Animal Studies Committee 
of the Washington University School of Medicine.
Generation of Syk−/− bone marrow chimeras
Syk+/− mice (Turner et al., 1995) were maintained on a 129.sv back-
ground (which does not carry the Ly-5.1 allele). Mice were genotyped by 
PCR using 5′-A G A G A A G C C C T G C C C A T G G A C -3′ (Syk+) and 5′-C C T T G-
G G A A A A G C G C C T C C C C T A C C C -3′ (Syk−) as forward primers in combi-
nation with the 5′-G T C C A G G T A G A C C T C T T T G G G C -3′ reverse primer. 
The products (86 and 120 bp for Syk+ and Syk−, respectively) were re-
solved on a 2.5% agarose gel. Syk−/− and littermate Syk+/? fetal liver cells 
were obtained from embryonic day 15–17 embryos from timed matings of 
Syk+/− carriers. Bone marrow chimeras were generated by intravenous in-
jection of unfractionated fetal liver cells into 6–8-wk-old lethally irradiated 
congenic recipient B6.SJL mice (carrying the Ly-5.1 allele). To evaluate 
marrow engraftment, chimeric marrow cells were incubated for 30 min 
with FITC-conjugated anti-Ly-5.1 mAb IgG. The cells were washed and 
 subjected to FACS analysis. Chimeras were used 4–8 wk after the bone 
marrow transplantation.
Macrophage isolation and osteoclast culture
Primary BMMs were prepared as described previously (Faccio et al., 
2003c) with slight modifi cation. Marrow was extracted from femora and 
tibia of 6–8-wk-old mice with α-MEM and cultured in α-MEM containing 
10% inactivated FBS, 100 IU/ml penicillin, and 100 μg/ml strepto-
mycin (a-10 medium) with 100 ng/ml MCSF (Zhao et al., 1999) in petri 
dishes. In c-Src−/− and Dap12−/−/FcRγ−/− mice, macrophages were 
cultured from their spleen cells. Cells were incubated at 37°C in 6% CO2 
for 3 d. Cells were washed with PBS and lifted with 1× trypsin/EDTA 
(Invitrogen) in PBS. A total of 5 × 103 cells were cultured in 200 μl 
α-MEM containing 10% heat-inactivated FBS with 100 ng/ml GST-RANKL 
and 26 ng/ml of mouse recombinant MCSF in 96-well tissue culture 
plates, some of which contained a sterile whale dentin slice. Cells were 
fi xed and stained for TRAP activity after 5 d in culture using a commer-
cial kit (387-A; Sigma- Aldrich). For actin ring staining, cells were fi xed 
in 4% PFA, permeabilized in 0.1% Triton X-100, rinsed in PBS, and 
immunostained with AlexaFluor488 phalloidin (Invitrogen). To quantitate 
resorption lacunae, cells were removed from the dentin slices with 2 N 
NaOH and mechanical agitation. Dentin slides were stained with Coo-
massie brilliant blue. For preosteoclast generation, 1.2 × 106 BMMs were 
plated per 10-cm tissue culture dish. After a 3-d culture in 26 ng/ml MCSF 
and 100 ng/ml GST-RANKL, TRAP-expressing preosteoclasts were lifted 
with 0.02% EDTA in PBS.
Retroviral transduction
WT human Syk, hβ3 integrin subunit, and their mutants in pMX retrovirus 
vector were transiently transfected into Plat-E packaging cells using 
FuGENE 6 Transfection Reagent (Roche). The virus was collected 48 h after 
transfection. BMMs were infected with the virus for 24 h in the presence of 
26 ng/ml MCSF and 4 μg/ml polybrene (Sigma-Aldrich). Cells were 
 selected in the presence of MCSF and 1 μg/ml blasticidin (Calbiochem) 
for 3 d before analysis of osteoclastogenesis.
Western blotting and immunoprecipitation
Cultured cells were washed twice with ice-cold PBS and lysed in radio-
immunoprecipitation buffer containing 20 mM Tris, pH 7.5, 150 mM NaCl, 
1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophos-
phate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 mM NaF, and 1× 
protease inhibitor mixture (Roche). After incubation on ice for 10 min, the 
cell lysates were clarifi ed by centrifugation at 15,000 rpm for 10 min. 40 μg 
of total lysates were subjected to 8 or 12% SDS-PAGE and transferred onto 
nitrocellulose membrane. The fi lters were blocked in 5% milk/TBS and 
0.1% Tween 20 for 1 h and incubated with primary antibodies at 4°C 
overnight followed by probing with secondary antibodies coupled with 
HRP (Santa Cruz Biotechnology, Inc.). The proteins were visualized using 
SuperSignal West Dura Extended Duration Substrate (Pierce Chemical 
Co.). Goat anti–β3-integrin pAb was purchased from Santa Cruz Biotech-
nology, Inc. Mouse anti-Syk mAb was purchased from Abcam, and anti-
phosphotyrosine mAb 4G10 was purchased from Upstate Biotechnology. 
Antiphospho-Vav3 (pY173) antibody was purchased from Biosource Inter-
national. mAb 327 directed against the c-Src protein and full-length c-Src 
cDNA were gifts from A. Shaw (Department of Pathology, Washington 
University School of Medicine, St. Louis, MO). Anti–c-Srcp-Y416 mAb was 
purchased from Cell Signaling. Anti–β1-integrin mAb was a gift from 
R. Hynes (Massachusetts Institute of Technology, Cambridge, MA). For immuno-
precipitation, BMMs were cultured with MCSF and RANKL in culture 
dishes for 3 d. Preosteoclasts were lifted and plated onto 5-μg/ml vitronectin-
 precoated dishes or cultured in suspension. Cells were washed in cold 
PBS and lysed on ice in radioimmunoprecipitation lysis buffer. 800 μg of 
protein was incubated with 2 μg monoclonal anti–human β3-integrin anti-
body (7G2; gift from E. Brown, University of California, San Francisco, San 
Francisco, CA) or polyclonal anti-Syk antibody (N19; Santa Cruz Biotech-
nology, Inc.) at 4°C overnight with rotation. Protein A/G agarose (Santa 
Cruz Biotechnology, Inc.) was then added and incubated with rotation for 
3 h at 4°C. Immunoprecipitates were washed three times in lysis buffer, and 
the beads were boiled in 2× SDS sample buffer for 5 min. After centrifuga-
tion, proteins were separated by 8 or 10% SDS polyacrylamide gels.
Osteoblast assays
Primary calvaria-derived osteoblasts were isolated in collagen-gel culture 
from 17.5-d Syk+/? or Syk−/− embryos (Udagawa et al., 2000). 5 × 104 
primary osteoblasts were maintained in 48-well plates in α-MEM for 3 d, 
after which osteoblastogenic medium consisting of α-MEM containing 
50 μg/ml ascorbic acid and 2 mM β-glycerophosphate was added. 20 d 
later, bone nodules were stained with Alizarin red.
In vitro adhesion assay
1.2 × 106 Syk+/? or Syk−/− BMMs were cultured with 100 ng/ml RANKL 
and 25 ng/ml MCSF for 3 d. Preosteoclasts were lifted with 0.02% EDTA 
in PBS and washed twice with α0 media. 1.5 × 105 preosteoclasts were 
Figure 9. Model of Syk-mediated organization of the osteo-
clast cytoskeleton. c-Src constitutively associates with the β3-
integrin subunit. αvβ3 is activated upon ligand (RGD) occupancy, 
which recruits Syk bound to the Y-phosphorylated ITAM 
 proteins FcRγ and Dap12 in an SH2 domain–dependent 
manner to the integrin–c-Src complex. αvβ3 occupancy also 
activates c-Src by phosphorylating Y416. In turn, activated 
c-Src phosphorylates Syk. Activated Syk phosphorylates 
Vav3, which shuttles Rac to its GTP-bound form, thereby organi-
zing the actin cytoskeleton.
SYK, C-SRC, αVβ3, AND ITAM REGULATE OSTEOCLASTS • ZOU ET AL. 887
plated on vitronectin (BD Biosciences)-precoated six-well nontissue culture-
treated plates for 5 or 10 min.
Rac activation assay
WT or Syk−/− preosteoclasts were lifted and plated onto 5-μg/ml vitro-
nectin-precoated dishes or were cultured in suspension. Cells were washed 
in cold PBS and lysed with lysis buffer. Levels of Rac1-bound GTP were 
determined according to the protocol of the Rac1 activation kit (Pierce 
Chemical Co.).
PTH-induced osteoclastogenesis in vivo
10 μg synthetic human PTH(1–34) (Bachem California Inc.) in 25 μl of ve-
hicle (1 mM HCl and 0.1% BSA) or vehicle alone were injected four times 
daily for 4 d into the subcutaneous tissue overlying the calvariae using a 
Hamilton syringe. After killing by CO2 narcosis, calvariae were removed 
intact, soft tissues were gently dissected, and the calvariae were fi xed in 
10% phosphate-buffered formalin for 24 h and were further processed as 
described previously (Zhao et al., 1999). Osteoclast number was deter-
mined using the Bioquant System (BIOQUANT Image Analysis). The 
mouse TRAP assay kit was purchased from Immunodiagnostic Systems Ltd. 
Serum TRAcP 5b was determined according to the manufacturer’s instruc-
tions of the mouse TRAP assay kit (Immunodiagnostic Systems Ltd). All in 
vivo experiments were approved by the Washington University Animal 
Studies Committee.
Analysis of mouse embryos
For whole-mount skeletal staining, 18-d embryos were eviscerated, fi xed in 
95% ethanol, and stained with Alcian blue and Alizarin red according to 
standard protocols (McLeod, 1980). For histological analyses, embryonic 
bones were fi xed in 10% formalin, and decalcifi ed sections were stained 
for TRAP activity.
Statistics
All data are expressed as means ± SD, and statistical signifi cance was 
calculated by t test.
Image acquisition and manipulation
Images from Figs. 1 (A–E), 2 B, 3 B, 4 B, 6 B, and 8 (A and G) were ac-
quired using a microscope (Eclipse E400; Nikon) with plan Fluor lenses 
at RT. All magnifi cations are 20× except for Fig. 2 B, which is 60×. 
Zimmerson oil (Fisher Scientifi c) served as the imaging medium in Fig. 2 B. 
Fluorochrome FITC was used in Fig. 1 (B and D). Images from Fig. 3 A 
were acquired using a microscope (MZFLIII; Leica) with a plan Apo 
1× lens (model 10447157; Leica) at RT. No imaging media or fl uoro-
chromes were used. Photographs were taken with a camera (MagnaFire 
S99802; Optronics) and displayed with MagnaFire software (version 
2.1B; Meyer Instruments) in all circumstances except Fig. 4 A. The images 
were organized in Photoshop (version 7.0.1; Adobe). Fig. 4 A was 
 acquired with a digital camera (Powershot A75; Canon) and organized 
in Photoshop.
Online supplemental material
Fig. S1 shows the generation of Syk chimeras. Fig. S2 shows that Syk defi -
ciency does not delay osteoclast differentiation or arrest intracellular signaling. 
Fig. S3 shows that bone density is increased in Syk−/− embryos. Fig. 4 
shows that Syk−/− preosteoclasts do not rapidly spread on αvβ3 ligand. 
Fig. S5 shows that the deletion of β3 integrin does not enhance Syk–β1 in-
tegrin association in osteoclasts. Online supplemental material is available 
at http://www.jcb.org/cgi/content/full/jcb.200611083/DC1.
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